{"study_name":"Study from Banna 2022.pdf","extracted_data":{"file_name":"Banna 2022.pdf","treatment_regimens":["pembrolizumab plus platinum-based chemotherapy"],"countries":["United Kingdom","Switzerland"],"populations":[{"n":164,"stage, histology":"IIIB/IVA, Adenocarcinoma","pdl1_status":"Negative"},{"pdl1_status":"Negative","n":113,"stage, histology":"IVB, Adenocarcinoma"},{"stage, histology":"IVB, Squamous","pdl1_status":"Negative","n":51},{"pdl1_status":"Negative","n":11,"stage, histology":"IIIB/IVA, Other"},{"stage, histology":"IIIB/IVA, Adenocarcinoma","pdl1_status":"Positive/High","n":151}],"results":{"pembrolizumab plus platinum-based chemotherapy":{"median_os":"12.7 months","median_pfs":"8.0 months","os_12_month":"52.2%","group_difference":"Patients with high NLR (â‰¥4) had significantly shorter OS (median 11.8 vs 14.9 months, p=0.02) and PFS (median 6.6 vs 9.0 months, p=0.018) than those with low values."}},"study_name":"Study from Banna 2022.pdf"},"_wandb":{"runtime":10},"status":"success","_timestamp":1.7426777227196531e+09,"_runtime":10.626222,"_step":0}